The Global Comprehensive Metabolic Panel (CMP) Testing Market size is expected to reach over US$ 18,380 Mn by 2026 and growing at a CAGR of around 7.0% from 2019 to 2026.
The Comprehensive Metabolic Panel (CMP) is a commonly ordered set of 14 tests that give doctor a significant data about the present status of kidneys, electrolyte, liver and acid / base balance as well as blood sugar and blood proteins. Abnormal findings, and in particular abnormal results combinations, may show an issue that needs to be resolved. The CMP is used as a wide screening instrument for diabetes, liver illness, and kidney disease conditions. It is also used for monitoring disease complications or side effects of drugs used for disease treatment. The CMP is regularly provided for a medical or annual physical examination as part of a blood work-up and is gathered by inserting a needle into arm's vein.
Market Dynamics
Healthcare awareness among consumers is one of the major factors expected to drive the CMP testing market. Many organizations around the globe are working to increase awareness of illnesses, treatment choices available, and early diagnosis and precautions advantages. The International Diabetes Foundation and the American Diabetes Association, for example, are some of the main organizations that emphasize the pressing need to diagnose and monitor diabetes through multiple awareness campaigns and other advertising methods. Furthermore, over the past few years, the landscape of medical diagnostics has experienced a fundamental shift, driven by the launch of enhanced diagnostic products and biomarker introduction. Recurrence and progression of disease, however, stay high, particularly among geriatric patients. Strong unmet demands pose a main chance in the CMP testing room to create first-class breakthrough diagnostics.
Above pie chart represents the global market share of comprehensive metabolic panel (CMP) testing market, by disease in 2018. The comprehensive metabolic panel market is segmented into disease, test type, end-use and region. The disease segment is bifurcated into kidney disease, liver disease, diabetes, and others. Kidney disease holds near about 42% share of comprehensive metabolic panel (CMP) testing market due to the rising incidence of kidney disease, increasing the amount of biopsy processes and growing demand for fresh chronic disease diagnostic methods. In addition, the accessibility of multiple kidney disease diagnostic tests also affects market growth. It is also anticipated that the growing number of market players will boost market growth during the forecast period. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) has indicated that kidney disease is often referred to as a "silent disease" as there are no symptoms in its early phases and may remain undetected.
Report Coverage
The market research study on “Comprehensive Metabolic Panel (CMP) Testing Market – Global Industry Analysis, Market Size, Opportunities and Forecast, 2019 - 2026, offers a detailed insights on the global comprehensive metabolic panel (CMP) testing market entailing insights on its different market segments. Market dynamics with drivers, restraints and opportunities with their impact are provided in the report. The report provides insights on global comprehensive metabolic panel (CMP) testing market, its product, power source, application, and major geographic regions. The report covers basic development policies and layouts of technology development processes. The comprehensive metabolic panel (CMP) testing market analysis is provided for major regional markets including North America, Europe, Asia-Pacific, Latin America, Middle East & Africa followed by major countries. For each region, the market size for different segments has been covered under the scope of report. The North America includes the global kidney disease market's highest share. The regional market stupendous performance is the consequence of increasing renal disease incidence, especially among geriatric population. In addition, in latest years, the availability of advanced healthcare services in the region has brought great revenue. Regional businesses also stress the need for more studies and development (R&D) and fresh goods to be developed. The growth in financing will also complement these factors, which will assist the region retain its top place throughout the assessment period. Europe has shown optimistic development, supported by high healthcare expenditure and increased awareness of kidney diseases. In addition, increasing public suggestions for CMP and rapidly increasing geriatric population are set to further elevate the market situation in this region. During the forecast period, Asia Pacific is anticipated to grow at the largest CAGR, driven by improved healthcare infrastructure, increased customer awareness, increased disposable income, and general economic development. The market is anticipated to experience fast development in demand for CMP testing in emerging countries such as China, India, and South Korea over the forecast period. The Middle East & Africa is increasing at a steady pace as the incidence of kidney diseases in the region has increased over the previous few years and is also anticipated to increase during forecast period.
The players profiled in the report are Sonic Healthcare, Quest Diagnostics, UNIPATH, Laboratory Corporation of America Holdings (LabCorp), Abbott, SYNLAB International GmbH and among others. The company operated in the market will increase their footprint in the global market by merger and acquisition of local players and focus on the research & development for advance technology.
Market Segmentation
Market By Disease
- Kidney Disease
- Liver Disease
- Diabetes
- Others
Market By Test Type
- Proteins
- Electrolytes
- Kidney Tests
- Liver Functional Tests
- Glucose
Market By End-Use
Market By Geography
- North America
- Europe
- UK
- Germany
- France
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- GCC
- South Africa
- Rest of Middle East & Africa
Table Of Content
CHAPTER 1. INDUSTRY OVERVIEW
1.1. Definition and Scope
1.1.1. Definition of Comprehensive Metabolic Panel (CMP) Testing
1.1.2. Market Segmentation
1.1.3. List of Abbreviations
1.2. Summary
1.2.1. Market Snapshot
1.2.2. Comprehensive Metabolic Panel (CMP) Testing Market By Disease
1.2.2.1. Global Comprehensive Metabolic Panel (CMP) Testing Market Revenue and Growth Rate Comparison By Disease (2015-2026)
1.2.2.2. Global Comprehensive Metabolic Panel (CMP) Testing Market Revenue Share By Disease in 2018
1.2.2.3. Kidney Disease
1.2.2.4. Liver Disease
1.2.2.5. Diabetes
1.2.2.6. Others
1.2.3. Comprehensive Metabolic Panel (CMP) Testing Market By Test Type
1.2.3.1. Global Comprehensive Metabolic Panel (CMP) Testing Market Revenue and Growth Rate Comparison By Test Type (2015-2026)
1.2.3.2. Proteins
1.2.3.3. Electrolytes
1.2.3.4. Kidney Tests
1.2.3.5. Liver Functional Tests
1.2.3.6. Glucose
1.2.4. Comprehensive Metabolic Panel (CMP) Testing Market By End-Use
1.2.4.1. Global Comprehensive Metabolic Panel (CMP) Testing Market Revenue and Growth Rate Comparison By End-Use (2015-2026)
1.2.4.2. Laboratories
1.2.4.3. PoC
1.2.5. Comprehensive Metabolic Panel (CMP) Testing Market By Geography
1.2.5.1. Global Comprehensive Metabolic Panel (CMP) Testing Market Revenue and Growth Rate Comparison by Geography (2015-2026)
1.2.5.2. North America Comprehensive Metabolic Panel (CMP) Testing Market Revenue and Growth Rate (2015-2026)
1.2.5.3. Europe Comprehensive Metabolic Panel (CMP) Testing Market Revenue and Growth Rate (2015-2026)
1.2.5.4. Asia-Pacific Comprehensive Metabolic Panel (CMP) Testing Market Revenue and Growth Rate (2015-2026)
1.2.5.5. Latin America Comprehensive Metabolic Panel (CMP) Testing Market Revenue and Growth Rate (2015-2026)
1.2.5.6. Middle East and Africa (MEA) Comprehensive Metabolic Panel (CMP) Testing Market Revenue and Growth Rate (2015-2026)
CHAPTER 2. MARKET DYNAMICS AND COMPETITION ANALYSIS
2.1. Market Drivers
2.2. Restraints and Challenges
2.3. Growth Opportunities
2.4. Porter’s Five Forces Analysis
2.4.1. Bargaining Power of Suppliers
2.4.2. Bargaining Power of Buyers
2.4.3. Threat of Substitute
2.4.4. Threat of New Entrants
2.4.5. Degree of Competition
2.5. Value Chain Analysis
2.6. Cost Structure Analysis
2.6.1. Raw Material and Suppliers
2.6.2. Manufacturing Process Analysis
2.7. Regulatory Compliance
2.8. Competitive Landscape, 2018
2.8.1. Player Positioning Analysis
2.8.2. Key Strategies Adopted By Leading Players
CHAPTER 3. MANUFACTURING PLANTS ANALYSIS
3.1. Capacity and Commercial Production Date of Global Comprehensive Metabolic Panel (CMP) Testing Major Manufacturers in 2018
3.2. Manufacturing Plants Distribution of Global Comprehensive Metabolic Panel (CMP) Testing Major Manufacturers in 2018
3.3. R&D Status and Technology Source of Global Comprehensive Metabolic Panel (CMP) Testing Major Manufacturers in 2018
3.4. Raw Materials Sources Analysis of Global Comprehensive Metabolic Panel (CMP) Testing Major Manufacturers in 2018
CHAPTER 4. COMPREHENSIVE METABOLIC PANEL (CMP) TESTING MARKET BY DISEASE
4.1. Global Comprehensive Metabolic Panel (CMP) Testing Revenue By Disease
4.2. Kidney Disease
4.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.3. Liver Disease
4.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.4. Diabetes
4.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.5. Others
4.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
CHAPTER 5. COMPREHENSIVE METABOLIC PANEL (CMP) TESTING MARKET BY TEST TYPE
5.1. Global Comprehensive Metabolic Panel (CMP) Testing Revenue By Test Type
5.2. Proteins
5.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.3. Electrolytes
5.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.4. Kidney Tests
5.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.5. Liver Functional Tests
5.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.6. Glucose
5.6.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.6.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
CHAPTER 6. COMPREHENSIVE METABOLIC PANEL (CMP) TESTING MARKET BY END-USE
6.1. Global Comprehensive Metabolic Panel (CMP) Testing Revenue By End-Use
6.2. Laboratories
6.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.3. PoC
6.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
CHAPTER 7. NORTH AMERICA COMPREHENSIVE METABOLIC PANEL (CMP) TESTING MARKET BY COUNTRY
7.1. North America Comprehensive Metabolic Panel (CMP) Testing Market Revenue and Growth Rate, 2015 - 2026 ($Million)
7.2. North America Comprehensive Metabolic Panel (CMP) Testing Market Revenue Share Comparison, 2015 & 2026 (%)
7.3. U.S.
7.3.1. U.S. Comprehensive Metabolic Panel (CMP) Testing Market Revenue and Forecast By Disease, 2015 - 2026 ($Million)
7.3.2. Market Revenue and Forecast By Test Type, 2015 - 2026 ($Million)
7.3.3. Market Revenue and Forecast By End-Use, 2015 - 2026 ($Million)
7.4. Canada
7.4.1. Market Revenue and Forecast By Disease, 2015 - 2026 ($Million)
7.4.2. Market Revenue and Forecast By Test Type, 2015 - 2026 ($Million)
7.4.3. Market Revenue and Forecast By End-Use, 2015 - 2026 ($Million)
CHAPTER 8. EUROPE COMPREHENSIVE METABOLIC PANEL (CMP) TESTING MARKET BY COUNTRY
8.1. Europe Comprehensive Metabolic Panel (CMP) Testing Market Revenue and Growth Rate, 2015 - 2026 ($Million)
8.2. Europe Comprehensive Metabolic Panel (CMP) Testing Market Revenue Share Comparison, 2015 & 2026 (%)
8.3. UK
8.3.1. Market Revenue and Forecast By Disease, 2015 - 2026 ($Million)
8.3.2. Market Revenue and Forecast By Test Type, 2015 - 2026 ($Million)
8.3.3. Market Revenue and Forecast By End-Use, 2015 - 2026 ($Million)
8.4. Germany
8.4.1. Market Revenue and Forecast By Disease, 2015 - 2026 ($Million)
8.4.2. Market Revenue and Forecast By Test Type, 2015 - 2026 ($Million)
8.4.3. Market Revenue and Forecast By End-Use, 2015 - 2026 ($Million)
8.5. France
8.5.1. Market Revenue and Forecast By Disease, 2015 - 2026 ($Million)
8.5.2. Market Revenue and Forecast By Test Type, 2015 - 2026 ($Million)
8.5.3. Market Revenue and Forecast By End-Use, 2015 - 2026 ($Million)
8.6. Spain
8.6.1. Market Revenue and Forecast By Disease, 2015 - 2026 ($Million)
8.6.2. Market Revenue and Forecast By Test Type, 2015 - 2026 ($Million)
8.6.3. Market Revenue and Forecast By End-Use, 2015 - 2026 ($Million)
8.7. Rest of Europe
8.7.1. Market Revenue and Forecast By Disease, 2015 - 2026 ($Million)
8.7.2. Market Revenue and Forecast By Test Type, 2015 - 2026 ($Million)
8.7.3. Market Revenue and Forecast By End-Use, 2015 - 2026 ($Million)
CHAPTER 9. ASIA-PACIFIC COMPREHENSIVE METABOLIC PANEL (CMP) TESTING MARKET BY COUNTRY
9.1. Asia-Pacific Comprehensive Metabolic Panel (CMP) Testing Market Revenue and Growth Rate, 2015 - 2026 ($Million)
9.2. Asia-Pacific Comprehensive Metabolic Panel (CMP) Testing Market Revenue Share Comparison, 2015 & 2026 (%)
9.3. China
9.3.1. Market Revenue and Forecast By Disease, 2015 - 2026 ($Million)
9.3.2. Market Revenue and Forecast By Test Type, 2015 - 2026 ($Million)
9.3.3. Market Revenue and Forecast By End-Use, 2015 - 2026 ($Million)
9.4. Japan
9.4.1. Market Revenue and Forecast By Disease, 2015 - 2026 ($Million)
9.4.2. Market Revenue and Forecast By Test Type, 2015 - 2026 ($Million)
9.4.3. Market Revenue and Forecast By End-Use, 2015 - 2026 ($Million)
9.5. India
9.5.1. Market Revenue and Forecast By Disease, 2015 - 2026 ($Million)
9.5.2. Market Revenue and Forecast By Test Type, 2015 - 2026 ($Million)
9.5.3. Market Revenue and Forecast By End-Use, 2015 - 2026 ($Million)
9.6. Australia
9.6.1. Market Revenue and Forecast By Disease, 2015 - 2026 ($Million)
9.6.2. Market Revenue and Forecast By Test Type, 2015 - 2026 ($Million)
9.6.3. Market Revenue and Forecast By End-Use, 2015 - 2026 ($Million)
9.7. South Korea
9.7.1. Market Revenue and Forecast By Disease, 2015 - 2026 ($Million)
9.7.2. Market Revenue and Forecast By Test Type, 2015 - 2026 ($Million)
9.7.3. Market Revenue and Forecast By End-Use, 2015 - 2026 ($Million)
9.8. Rest of Asia-Pacific
9.8.1. Market Revenue and Forecast By Disease, 2015 - 2026 ($Million)
9.8.2. Market Revenue and Forecast By Test Type, 2015 - 2026 ($Million)
9.8.3. Market Revenue and Forecast By End-Use, 2015 - 2026 ($Million)
CHAPTER 10. LATIN AMERICA COMPREHENSIVE METABOLIC PANEL (CMP) TESTING MARKET BY COUNTRY
10.1. Latin America Comprehensive Metabolic Panel (CMP) Testing Market Revenue and Growth Rate, 2015 - 2026 ($Million)
10.2. Latin America Comprehensive Metabolic Panel (CMP) Testing Market Revenue Share Comparison, 2015 & 2026 (%)
10.3. Brazil
10.3.1. Market Revenue and Forecast By Disease, 2015 - 2026 ($Million)
10.3.2. Market Revenue and Forecast By Test Type, 2015 - 2026 ($Million)
10.3.3. Market Revenue and Forecast By End-Use, 2015 - 2026 ($Million)
10.4. Mexico
10.4.1. Market Revenue and Forecast By Disease, 2015 - 2026 ($Million)
10.4.2. Market Revenue and Forecast By Test Type, 2015 - 2026 ($Million)
10.4.3. Market Revenue and Forecast By End-Use, 2015 - 2026 ($Million)
10.5. Rest of Latin America
10.5.1. Market Revenue and Forecast By Disease, 2015 - 2026 ($Million)
10.5.2. Market Revenue and Forecast By Test Type, 2015 - 2026 ($Million)
10.5.3. Market Revenue and Forecast By End-Use, 2015 - 2026 ($Million)
CHAPTER 11. MIDDLE EAST & AFRICA COMPREHENSIVE METABOLIC PANEL (CMP) TESTING MARKET BY COUNTRY
11.1. Middle East & Africa Comprehensive Metabolic Panel (CMP) Testing Market Revenue and Growth Rate, 2015 - 2026 ($Million)
11.2. Middle East & Africa Comprehensive Metabolic Panel (CMP) Testing Market Revenue Share Comparison, 2015 & 2026 (%)
11.3. GCC
11.3.1. Market Revenue and Forecast By Disease, 2015 - 2026 ($Million)
11.3.2. Market Revenue and Forecast By Test Type, 2015 - 2026 ($Million)
11.3.3. Market Revenue and Forecast By End-Use, 2015 - 2026 ($Million)
11.4. South Africa
11.4.1. Market Revenue and Forecast By Disease, 2015 - 2026 ($Million)
11.4.2. Market Revenue and Forecast By Test Type, 2015 - 2026 ($Million)
11.4.3. Market Revenue and Forecast By End-Use, 2015 - 2026 ($Million)
11.5. Rest of Middle East & AFRICA
11.5.1. Market Revenue and Forecast By Disease, 2015 - 2026 ($Million)
11.5.2. Market Revenue and Forecast By Test Type, 2015 - 2026 ($Million)
11.5.3. Market Revenue and Forecast By End-Use, 2015 - 2026 ($Million)
CHAPTER 12. COMPANY PROFILE
12.1. Sonic Healthcare
12.1.1. Company Snapshot
12.1.2. Overview
12.1.3. Financial Overview
12.1.4. Type Portfolio
12.1.5. Key Developments
12.1.6. Strategies
12.2. Quest Diagnostics
12.2.1. Company Snapshot
12.2.2. Overview
12.2.3. Financial Overview
12.2.4. Type Portfolio
12.2.5. Key Developments
12.2.6. Strategies
12.3. UNIPATH
12.3.1. Company Snapshot
12.3.2. Overview
12.3.3. Financial Overview
12.3.4. Type Portfolio
12.3.5. Key Developments
12.3.6. Strategies
12.4. Laboratory Corporation of America Holdings (LabCorp)
12.4.1. Company Snapshot
12.4.2. Overview
12.4.3. Financial Overview
12.4.4. Type Portfolio
12.4.5. Key Developments
12.4.6. Strategies
12.5. Abbott
12.5.1. Company Snapshot
12.5.2. Overview
12.5.3. Financial Overview
12.5.4. Type Portfolio
12.5.5. Key Developments
12.5.6. Strategies
12.6. SYNLAB International GmbH
12.6.1. Company Snapshot
12.6.2. Overview
12.6.3. Financial Overview
12.6.4. Type Portfolio
12.6.5. Key Developments
12.6.6. Strategies
12.7. Others
12.7.1. Company Snapshot
12.7.2. Overview
12.7.3. Financial Overview
12.7.4. Type Portfolio
12.7.5. Key Developments
12.7.6. Strategies
CHAPTER 13. RESEARCH APPROACH
13.1. Research Methodology
13.1.1. Initial Data Search
13.1.2. Secondary Research
13.1.3. Primary Research
13.2. Assumptions and Scope
